ClinicalTrials.Veeva

Menu

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Tango Therapeutics logo

Tango Therapeutics

Status and phase

Enrolling
Phase 2
Phase 1

Conditions

Locally Advanced Solid Tumor

Treatments

Drug: TNG908

Study type

Interventional

Funder types

Industry

Identifiers

NCT05275478
TNG908-C101

Details and patient eligibility

About

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 192 participants.

Full description

This is a Phase 1/2 multi-center, open label study in solid tumor patients (including glioblastoma) who have a confirmed homozygous MTAP deletion in their tumor. The Phase 1 portion is a dose escalation study of oral TNG908 in patients with confirmed MTAP-deleted solid tumors. In Phase 2, 6 expansion arms defined by confirmed MTAP-deleted tumor types will enroll in parallel at the RP2D of TNG908. In both parts of the study participants who tolerate the drug may continue treatment until disease progression.

Enrollment

192 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age: ≥18 years-of-age at the time of signature of the main study ICF
  2. Performance status: ECOG Performance Score of 0 to 1 or Karnofsky performance status score ≥70.
  3. Confirmed histologic or cytologic diagnosis of a locally advanced, metastatic, and/or unresectable solid tumor or for GBM, have R/R disease.
  4. Prior standard therapy, as available
  5. Documented bi-allelic (homozygous) deletion of MTAP in a tumor detected by next- generation sequencing or absence of MTAP protein in a tumor detected by IHC.
  6. Adequate organ function/reserve per local labs
  7. Adequate liver function per local labs
  8. Adequate renal function per local labs
  9. Negative serum pregnancy test result at screening
  10. Written informed consent must be obtained according to local guidelines

Exclusion criteria

  1. Known allergies, hypersensitivity, or intolerance to TNG908 or its excipients

  2. Uncontrolled intercurrent illness that will limit compliance with the study requirements

  3. Active infection requiring systemic therapy

  4. Currently participating in or has planned participation in a study of another investigational agent or device

  5. Impairment of GI function or disease that may significantly alter the absorption of oral TNG908

  6. Active prior or concurrent malignancy.

  7. Central nervous system metastases associated with progressive neurological symptoms

  8. Current active liver disease from any cause

  9. Known to be HIV positive, unless all of the following criteria are met:

    1. CD4+ count ≥300/μL
    2. Undetectable viral load
    3. Receiving highly active antiretroviral therapy
  10. Clinically relevant cardiovascular disease

  11. A female patient who is pregnant or lactating

  12. Patient is unwilling or unable to comply with the scheduled visits, drug administration plan, laboratory tests, biopsy, or other study procedures and study restrictions

  13. Patient has a prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, may affect the safety of the patient or impair the assessment of study results

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

192 participants in 7 patient groups

Dose Escalation
Experimental group
Description:
Participants with MTAP-deleted solid tumors will receive escalating doses of TNG908 to estimate the MTD
Treatment:
Drug: TNG908
Dose Expansion in NSCLC
Experimental group
Description:
Participants with MTAP-deleted NSCLC (squamous and non squamous) will receive TNG908 at the identified RP2D
Treatment:
Drug: TNG908
Dose Expansion in Mesothelioma
Experimental group
Description:
Participants with MTAP-deleted mesothelioma will receive TNG908 at the identified RP2D
Treatment:
Drug: TNG908
Dose Expansion in Pancreatic Ductal Adenocarcinoma
Experimental group
Description:
Participants with MTAP-deleted pancreatic ductal adenocarcinoma will receive TNG908 at the identified RP2D
Treatment:
Drug: TNG908
Dose Expansion in Sarcoma
Experimental group
Description:
Participants with MTAP-deleted sarcoma (soft tissue and bone) will receive TNG908 at the identified RP2D
Treatment:
Drug: TNG908
Dose Expansion in solid tumors
Experimental group
Description:
Participants with other MTAP-deleted solid tumors will receive TNG908 at the identified RP2D
Treatment:
Drug: TNG908
Dose Expansion in Glioblastoma
Experimental group
Description:
Participants with MTAP-deleted relapsed/refractory glioblastoma will receive TNG908 at the identified RP2D
Treatment:
Drug: TNG908

Trial contacts and locations

15

Loading...

Central trial contact

Tango Clinical Trials

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems